COMPASS Pathways upgraded by Oppenheimer with a new price target
$CMPS
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2025 | $15.00 | Perform → Outperform | Oppenheimer |
| 6/23/2025 | $11.00 → $6.00 | Outperform → In-line | Evercore ISI |
| 2/27/2025 | $11.00 | Buy | Stifel |
| 7/23/2024 | $23.00 | Outperform | RBC Capital Mkts |
| 4/1/2024 | $30.00 | Overweight | Morgan Stanley |
| 12/12/2023 | $16.00 | Buy | Deutsche Bank |
| 11/21/2022 | $33.00 | Buy | Berenberg |
| 11/1/2022 | $34.00 | Buy | Loop Capital |
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD) Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted i
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company's commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders' perspectives on the current treatment landscape and the significant unmet need in treating both TRD and PTSD. The company's collaboration partners will discuss patient care pathways, provider economics for multi-hour treatments, and the develop
8-K - COMPASS Pathways plc (0001816590) (Filer)
SCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)
10-Q - COMPASS Pathways plc (0001816590) (Filer)
4 - COMPASS Pathways plc (0001816590) (Issuer)
3 - COMPASS Pathways plc (0001816590) (Issuer)
4 - COMPASS Pathways plc (0001816590) (Issuer)
Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00
Evercore ISI downgraded COMPASS Pathways from Outperform to In-line and set a new price target of $6.00 from $11.00 previously
Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO. Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathw
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is
SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)
SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)
SC 13G - COMPASS Pathways plc (0001816590) (Subject)